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Dried blood spots that had been stored ambiently for 3 to 6 years lost approximately 1 log10 of human
immunodeficiency virus type 1 (HIV-1) RNA, but the majority could still be genotyped for resistance. Nevira-
pine resistance was found in 7/16 (43.5%) HIV-1-positive HIVNET 024 infants at 4 to 6 weeks, but no resistance
was found at other time points.
The use of single-dose nevirapine (sdNVP) has become part
of standard care in the prevention of mother-to-child trans-
mission of human immunodeficiency virus (HIV) in many parts
of the world. Development of resistance to NVP in HIV-
infected infants despite sdNVP treatment has been examined
in some trials, but not in HIVNET 024, in which all mothers
and infants received sdNVP (6). Dried blood spots (DBS) had
been collected from the infants for diagnosis, and these were
available for further testing of NVP resistance. Several groups
have used DBS for resistance testing, using home brew assays
(8, 10, 11) or the Siemens TruGene HIV-1 genotyping assay
(7). However, the DBS were at least 3 years old at the time of
this study.
DBS are an easy way to collect and ship specimens for
diagnostic testing for HIV and preclude the necessity of a
phlebotomist and maintenance of a cold chain (4, 9). Previous
studies have shown that DBS that are stored at 20°C or
70°C are stable for at least 6 years (8) and that ambient
storage keeps DBS stable for at least 1 year (3). As to whether
old DBS would work for sequencing, one group had found that
DBS stored for 5 to 6 years at 20°C or 70°C could be
sequenced with a home brew assay and that DBS stored am-
biently 5 to 6 years could not be sequenced (8). The HIVNET
024 DBS had been stored ambiently 3 to 6 years, so we tested
them to see if sequencing could still be done.
The DBS had been made from 50 l of collected whole
blood per spot on Whatman 903 cards. After drying at an
ambient temperature, the cards were stored in zipper bags with
desiccant at an ambient temperature in multiple countries in
Africa and then in North Carolina. The UNC Institutional
Review Board determined that this study fell under exemption
4 for Human Subjects Research because the samples were
preexisting samples that did not have any identifying informa-
tion linked to them.
DBS from 33 infants born in Tanzania (where subtypes A, C,
and D are prevalent) were used for Boom extraction of total
nucleic acid (2) for HIV-1 RNA quantitation with the Roche
Amplicor Monitor version 1.5 microwell plate assay (standard
method), and the viral loads (VLs) were compared to those
found in the previous VL test, which used the same method.
An entire spot was cut from the paper by using scissors and
placed in 9 ml NucliSens extraction buffer (bioMérieux,
Durham, NC) with 6.7 l Roche quantitation standard for
Boom extraction (2). The scissors were decontaminated with
bleach, water, and ethanol between uses. At the end of the
Boom extraction, 35 l of eluate was removed from the silica
beads to a new tube. Nine microliters of the eluate was re-
moved to a second new tube, and Roche Monitor diluent was
added to bring the volume up to 100 l for VL testing. Sev-
enteen microliters of the original eluate was used per sequenc-
ing reaction. A single negative control was included with each
set of samples extracted. A total of 47 samples were tested. The
samples used were one or both of the first two samples that
tested positive for each infant, who ranged from a few days to
15 months of age at the time of sampling. We compared the
new VLs to those originally determined by the same method
within 3 months of collection (except for five samples, which
were originally tested for VL 1.5 to 1.8 years after collection).
For the DBS samples that had been tested within 3 months, the
repeat VLs were on average 1.04 log10 lower (P  0.00002;
Student’s t test; range of drop, 0.42 to 2.12 log10) than those
found in prior determinations with the same DBS cards (Fig.
1). The five samples that had been tested for the first time after
a 1.5- to 1.8-year delay had lower RNA levels in the second
assay than in the first, with an average drop of 0.50 log10
(range, 0.047 to 0.78), although the drop was not statistically
significant (P  0.26).
Extracted RNA from DBS with 1,000 copies/ml in the
most recent testing were used for TruGene genotyping (45
samples total). TruGene sequencing was successful for 31 of 45
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samples (68.9%), which represented 23 of the 31 infants
(74.2%) for whom there was sufficient RNA recovery for se-
quencing. The samples for which sequencing was unsuccessful
had VLs in the same range (1,481 to 286,766 cp/ml) as those
for which sequencing was successful (1,510 to 279,470 cp/ml; P
 0.67). The ages of the DBS were also similar for the two
groups, with average ages of 4.3 years for the samples that
sequenced and 4.1 years for the samples that did not sequence
(P  0.77). Four of the samples that did not sequence were
from infants from whom we obtained a sample that we could
sequence at another time point, while we could not obtain
sequences from eight of the infants (two had two samples that
could not be sequenced). Sequences were checked for cross-
contamination by making an alignment and a phylogenetic tree
of the sequences, using CLC Sequence Viewer 4 (CLC Bio
A/S). Subtypes of sequences were determined using the REGA
HIV-1 subtyping tool (http://www.bioafrica.net/virus-genotype
/html/subtypinghiv.html). The sequences that were obtained
indicated that 10 infants were infected with HIV-1 subtype A,
8 were infected with subtype C, 4 were infected with subtype D,
and 1 was infected with CRF10_CD.
Sequences were also analyzed for resistance mutations by
using the Stanford University HIV Drug Resistance Database
(http://hivdb.stanford.edu/pages/algs/HIVdb.html). NVP resis-
tance was found in seven infants (two infected with subtype A,
three infected with subtype C, and two infected with subtype
D) (Table 1). Six of the seven infants with NVP resistance had
a positive HIV RNA test result at birth (presumed in utero
transmission), but NVP resistance was not seen in any birth
samples that we tested. The seventh infant had a negative HIV
RNA test result at birth and had a mutation associated with
intermediate NVP resistance (Stanford University HIV Drug
Resistance Database) at the 6-week time point. NVP resis-
tance was not found in any of the other samples tested, includ-
ing 9 birth samples, 2 samples at 12 weeks, and 4 samples from
later time points. Overall, six of nine infants who were positive
at birth and could be sequenced at 6 weeks had NVP resistance
(66.7%), while only one of six infants who were HIV RNA
negative at birth and could be sequenced at 6 weeks had NVP
resistance (16.7%), albeit at an intermediate level.
To determine whether the samples that did not amplify were
from one specific subtype or recombinant, we used the plasma
samples from the mothers of the infants for whom we could
not get a sequence. Of three samples tested, we found that two
were subtype C and one was subtype A. Therefore, there did
not appear to be a subtype bias in the samples that could not
be sequenced. Also, the ability of the maternal virus to be
sequenced suggests that it was not sequence differences at the
primer sites that prevented successful sequencing. Other pos-
sible reasons for our inability to generate sequences from some
DBS include fragmented RNA in these samples or an inhibitor
of PCR. Using more-recent DBS from UNC Hospitals, we
found that some samples had an inhibitor that could be over-
come by using half as much of the RNA (J. A. E. Nelson,
unpublished observations). We were unable to confirm the
possibility of inhibition in the old samples, however.
These results for NVP resistance in infants in the HIVNET
024 trial can be compared with those seen in other trials. In the
sdNVP arm of the HIVNET 012 trial, 46% of infected infants
had NVP resistance at 6 to 8 weeks (5). A meta-analysis of nine
FIG. 1. Correlation between VLs determined with Roche Monitor version 1.5 microwell assays within 3 months of DBS collection (first VL)
and after 3 to 6 years of room temperature storage (second VL).













1 6 A Y188C Positive No sample




3 6 C Y181C Positive None
4 6 D Y181C Positive None
5 6 C V106 M Positive None
6 6 D Y181C Positive None
7 6 A K238Na Negative Not
applicable
a Mutation associated with intermediate NVP resistance level (Stanford Uni-
versity HIV Drug Resistance Database).
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sdNVP studies, including HIVNET 012, showed that just over
half of HIV-positive infants had NVP resistance at 4 to 8 weeks
of age after just being exposed to NVP, compared with 16.5%
of HIV-positive infants exposed to NVP plus other antiretro-
viral drugs (1). Our overall percentage of NVP resistance in
infants at 6 weeks was 43.8%, which is in line with the other
studies of sdNVP alone. Most of the studies in this meta-
analysis indicated that the infants had mutations different from
those in their mothers, suggesting that the resistance was ac-
quired in the infants after transmission. Our data support that
hypothesis, since we saw no NVP resistance in any of the birth
samples.
Data from a 6-week extended-dose NVP study indicate that,
at least among infants in the sdNVP arm of the study, 70% of
infants who were HIV positive at birth and 36% of infants who
were HIV negative at birth had NVP resistance at 6 weeks
(4a). These data are not statistically different from our results
of 66.7% and 16.7%, respectively (P  1.00 and 0.61, respec-
tively; Fisher’s exact test). These differences in rate of NVP
resistance among infants indicate that the timing of sdNVP
administration to the infant relative to HIV transmission is an
important factor, since in utero transmission would result in
higher VL when NVP was given than would intrapartum trans-
mission.
In this study, we found that DBS that have been stored
properly at room temperature (sealed in a plastic bag with
desiccant) do show a drop in VL of approximately 1 log10 over
3 to 6 years but that if the samples had relatively high VLs
originally (10,000 cp/ml), as is commonly found with newly
infected infants, these spots can be used for resistance testing
with the TruGene system. Our sequencing results indicate that
usable sequences can be obtained from DBS for subtypes A, C,
and D and the CRF10_CD recombinant form.
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